Keyphrases
Tolerability
100%
Chemotherapy
100%
Gastric Cancer
100%
Second-line Chemotherapy
100%
Disease Control
100%
Nivolumab
100%
Odds Ratio
42%
Disease Groups
42%
Third-line Chemotherapy
42%
Progressive Disease
42%
Over 65
42%
Immune-related Adverse Events
28%
Number of Patients
14%
Monotherapy
14%
University Hospital
14%
Tumor
14%
Japanese Patients
14%
Complete Response
14%
Partial Response
14%
Stable Disease
14%
Treatment Outcome
14%
Second-line Treatment
14%
Inflammatory Activity
14%
Pharmacology, Toxicology and Pharmaceutical Science
Stomach Cancer
100%
Tolerability
100%
Disease
100%
Chemotherapy
100%
Second-Line Chemotherapy
100%
Nivolumab
100%
Adverse Event
20%
Neoplasm
10%
Monotherapy
10%
Medicine and Dentistry
Disease
100%
Stomach Cancer
100%
Second-Line Chemotherapy
100%
Nivolumab
100%
Odds Ratio
42%
Progressive Disease
42%
Immune-Related Adverse Events
28%
Neoplasm
14%
Monotherapy
14%
Immunology and Microbiology